论文部分内容阅读
目的探讨阿托伐他汀联合参脉注射液治疗慢性心力衰竭(心衰)临床疗效。方法选取慢性心衰患者75例,随机分为观察组36例,对照组39例。两组患者均予以强心剂、利尿剂、血管紧张素转换酶抑制剂、β受体阻滞剂等常规治疗。对照组在常规治疗的基础上,给予阿托伐他汀;观察组患者则应用阿托伐他汀联合参麦注射液治疗。阿托伐他汀(20mg/d,睡前口服)、参脉注射液(50ml加入5%葡萄糖注射液或生理盐水250ml中静脉滴注,每天1次)疗程均为2周。2周后观察心功能NYHA分级评定、6min步行实验、左室射血分数(LVEF)、左室收缩期末内径(LVESD)、左室舒张末内径(LVEDD)。结果两组患者治疗后NYHA分级、6min步行距离、LVEF及相关指标较治疗前改善(P<0.05);观察组6min步行距离高于对照组[(294.5±86.7)m vs.(278.4±76.1)m](P<0.05)。结论阿托伐他汀联合参脉注射液治疗慢性心衰安全有效。
Objective To investigate the clinical efficacy of atorvastatin combined with Shenmai Injection in treating chronic heart failure (heart failure). Methods 75 patients with chronic heart failure were randomly divided into observation group 36 cases and control group 39 cases. Two groups of patients were given cardiac, diuretics, angiotensin-converting enzyme inhibitors, β-blockers and other conventional treatment. The control group was given atorvastatin on the basis of routine treatment, while the observation group was treated with atorvastatin combined with Shenmai injection. Atorvastatin (20mg / d, bedtime oral), Shen Mai injection (50ml added 5% glucose injection or saline 250ml intravenous infusion, once daily) for 2 weeks. After 2 weeks, NYHA classification, 6min walking test, left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) were observed. Results The NYHA classification, walking distance at 6min, LVEF and related parameters were improved in both groups after treatment (P <0.05). The walking distance at 6min in observation group was higher than that in control group [(294.5 ± 86.7) m vs. (278.4 ± 76.1) m] (P <0.05). Conclusions Atorvastatin combined with Shenmai Injection is safe and effective in the treatment of chronic heart failure.